Latest clinical information on Zika virus available at info centers on Elsevier Connect and The Lancet

To help healthcare professionals, medical researchers and the public understand the ongoing outbreak of the Zika virus, Elsevier has created a Zika Virus Resource Center on Elsevier's public news and information website. In addition, The Lancet, one of Elsevier's top medical journals, has created a Zika virus resource centre on its website, where healthcare professionals can read the latest updates, research, reviews, editorials, correspondence and commentary on the outbreak.

Both resource centers are free to the public
"With our virus resource center on The Lancet, and with one on Elsevier Connect, we strive to bring together the best available evidence on Zika to assist researchers, policy makers and health workers in understanding the effects of the outbreak and how best to respond," said Richard Horton, Editor-in-Chief of The Lancet. "Decisions affecting the public's health should be supported by the best available evidence, and our resource center will aim to keep policy makers and others updated with the latest research and analysis as developments unfold."

Both info centers are advised by clinicians and professional editors and will be updated with the most current research and evidence-based information available. Elsevier publishes about 25 percent of the world’s scientific content, including thousands of textbooks and journals, drug information, clinical guidelines and patient education.

The Elsevier Connect information center also links to other authoritative resources, including the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). In addition, the site features links to data from Scopus and SciVal, which provide insight into global Zika research trends, and Mendeley, which established a Zika Virus Reference Group to share references to relevant articles to support the research community's work in finding a vaccine.

Both The Lancet and Elsevier Connect developed similar resource centers during the Ebola epidemic.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...